Press Releases Exact Sciences Corporation

Stocks

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-20 pm EDT			5-day change	1st Jan Change
104.91 ^USD	+0.95%		-.--%	+3.30%

Mar. 24	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Biotechnology Select Industry Index	CI
Mar. 24	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Global BMI Index	CI

Press Releases

Mar. 17	Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026	BU
Mar. 04	Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year	BU
Feb. 20	Exact Sciences Stockholders Approve Acquisition by Abbott	BU
Feb. 13	Exact Sciences: Q4 Earnings Snapshot	AQ
Feb. 13	Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results	BU
Feb. 03	Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests	BU
Feb. 03	Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide	BU
Dec. 31	Tel Aviv University: TAU and Google Israel Launch New Three-Year Program to Advance Core AI Research	AQ
Dec. 18	Exact Sciences : Announces First Participant Enrolled in the CRANE Study, a Multi-Cancer Early Detection Clinical Evaluation in Japan	PU
Dec. 12	Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect MRD Test in Early Triple-Negative Breast Cancer at SABCS	AQ
Dec. 11	Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS	BU
Nov. 24	Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium	BU
Nov. 24	EXAS Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Exact Sciences to Abbott Laboratories	AQ
Nov. 21	Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS	BU
Nov. 10	Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome’s Blood-Based Colorectal Cancer Screening Tests	BU
Nov. 07	Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test	BU
Nov. 04	Exact Sciences to Participate in November Investor Conference	BU
Nov. 03	Exact Sciences: Q3 Earnings Snapshot	AQ
Nov. 03	Exact Sciences Announces Third Quarter 2025 Results	BU
25-10-27	Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps	BU
25-10-08	Exact Sciences Corp. - New Study in Journal of the National Cancer Institute Finds Cologuard Plus Provides the Most Life-Years Gained with the Fewest Colonoscopies	AQ
25-10-08	Exact Sciences Schedules Third Quarter 2025 Earnings Call	BU
25-10-07	New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies	BU
25-09-23	Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard Test	AQ
25-09-22	Exact Sciences : Latest Corporate Presentation	PU